{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:30:36Z","timestamp":1784903436128,"version":"3.55.0"},"reference-count":41,"publisher":"Centre for Evaluation in Education and Science (CEON\/CEES)","issue":"7","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/BY\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Biochemistry"],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:p>Background: This study aimed to explore the clinical efficacy of probiotics plus quadruple therapy on Serum levels of tumour necrosis factor-a (TNF-a), interleukin-6 (IL-6), C-reactive protein (CRP), gastrin (GAS) and motilin (MTL) in treating Helicobacter pylori (Hp)-positive gastric ulcer (GU). Methods: One hundred and twenty-four patients with Hp-positive GU treated in our hospital from January 2021 to January 2024 were randomly separated into control and observation groups. The former received conventional quadruple therapy, and the latter received tetralogy of viable bifidobacterium tablets combined with conventional quadruple therapy. The clinical efficacy, Hp eradication rate, levels of inflammatory cytokines and gastrointestinal hormone, incidence of adverse reactions, and quality of life were compared in 2 groups. Results: The total effective rate of the observation group was 96.77%, higher than that of the control group (82.25%). The Hp eradication rate in the observation group was higher than in the control group. After therapy, IL-6, TNF-a and CRP levels declined in 2 groups, and those in the observation group presented lower compared to the control group. After therapy, MLT level was elevated while GAS level was declined in 2 groups, and the improvements of MLT and GAS levels in the observation group were more significant than those in the control group. The incidence of diarrhoea in the observation group was lower than that in the control group, and there was no difference in the incidence of nausea and abdominal distension between 2 groups. Conclusions: This study investigated the effects of probiotics combined with quadruple therapy on serum levels of tumour necrosis factor-a (TNF-a), interleukin-6 (IL-6), C-reactive protein (CRP), gastrin (GAS), and motilin (MTL) in patients with Helicobacter pylori (Hp)-positive gastric ulcer (GU). The results demonstrated that this combined treatment approach significantly improved Hp eradication rates, reduced inflammatory cytokine levels, and regulated gastrointestinal hormone secretion. Furthermore, patients receiving probiotics with quadruple therapy experienced better maintenance of intestinal flora balance and enhanced overall quality of life than those receiving conventional quadruple therapy alone. These findings suggest that integrating probiotics into standard treatment protocols for Hp-positive GU may offer a safer and more effective therapeutic strategy, addressing inflammation control and gastrointestinal health while improving patient outcomes.<\/jats:p>","DOI":"10.5937\/jomb0-55373","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T03:09:27Z","timestamp":1746414567000},"page":"1598-1607","source":"Crossref","is-referenced-by-count":2,"title":["Alteration of serum levels of tumour necrosis factor-a (TNF-a), interleukin-6 (IL-6), C-reactive protein (CRP), gastrin (GAS) and motilin (MTL) after treatment in the Helicobacter pylori-positive gastric ulcer"],"prefix":"10.5937","volume":"44","author":[{"given":"Yunxiang","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3964","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Gong H, Zhao N, Zhu C, Luo L, Liu S. Treatment of gastric ulcer, traditional Chinese medicine may be a better choice. J Ethnopharmacol 2024; 324: 117793.;","DOI":"10.1016\/j.jep.2024.117793"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Malfertheiner P, Camargo MC, El-Omar E, Liou JM, Peek R, Schulz C, et al. Helicobacter pylori infection. Nature reviews Disease Primers 2023; 9(1): 19.;","DOI":"10.1038\/s41572-023-00431-8"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Lee YC, Dore MP, Graham DY. Diagnosis and Treatment of Helicobacter pylori Infection. Annual Review of Medicine 2022; 73: 183-95.;","DOI":"10.1146\/annurev-med-042220-020814"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Sousa C, Ferreira R, Azevedo NF, Oleastro M, Azeredo J, Figueiredo C, et al. Helicobacter pylori infection: from standard to alternative treatment strategies. Critical Reviews in Microbiology 2022; 48(3): 376-96.;","DOI":"10.1080\/1040841X.2021.1975643"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Hwang JJ, Lee DH, Lee AR, Yoon H, Shin CM, Park YS, et al. Characteristics of gastric cancer in peptic ulcer patients with Helicobacter pylori infection. World J Gastroenterol 2015; 21(16): 4954-60.;","DOI":"10.3748\/wjg.v21.i16.4954"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Zhou L, Lu H, Song Z, Lyu B, Chen Y, Wang J, et al. 2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment. Chin Med J (Engl) 2022; 135(24): 2899-910.;","DOI":"10.1097\/CM9.0000000000002546"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Chen L, Xu W, Lee A, He J, Huang B, Zheng W, et al. The impact of Helicobacter pylori infection, eradication therapy and probiotic supplementation on gut microenvironment homeostasis: An open-label, randomised clinical trial. EBioMedicine 2018; 35: 87-96.;","DOI":"10.1016\/j.ebiom.2018.08.028"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Yao G, Fan X, Lu D. Efficacy and safety of probiotic-supplemented bismuth quadruple therapy for the treatment of Helicobacter pylori infection: a systematic review and meta-analysis. The Journal of International Medical Research 2023; 51(10): 3000605231203841.;","DOI":"10.1177\/03000605231203841"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Nabavi-Rad A, Sadeghi A, Asadzadeh Aghdaei H, Yadegar A, Smith SM, Zali MR. The double-edged sword of probiotic supplementation on gut microbiota structure in Helicobacter pylori management. Gut microbes 2022; 14(1): 2108655.;","DOI":"10.1080\/19490976.2022.2108655"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Goderska K, Agudo Pena S, Alarcon T. Helicobacter pylori treatment: antibiotics or probiotics. Applied Microbiology and Biotechnology 2018; 102(1): 1-7.;","DOI":"10.1007\/s00253-017-8535-7"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Qureshi N, Li P, Gu Q. Probiotic therapy in Helicobacter pylori infection: a potential strategy against a serious pathogen? Applied Microbiology and Biotechnology 2019; 103(4): 1573-88.;","DOI":"10.1007\/s00253-018-09580-3"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Bai X, Zhu M, He Y, Wang T, Tian D, Shu J. The impacts of probiotics in eradication therapy of Helicobacter pylori. Archives of Microbiology 2022; 204(12): 692.;","DOI":"10.1007\/s00203-022-03314-w"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"He C, Xie Y, Zhu Y, Zhuang K, Huo L, Yu Y, et al. Probiotics modulate gastrointestinal microbiota after Helicobacter pylori eradication: A multicenter randomised double-blind placebo-controlled trial. Front Immunol 2022; 13: 1033063.;","DOI":"10.3389\/fimmu.2022.1033063"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Teo BJX, Koh JSB, Jiang L, Allen JC, Yeo SJ, Howe TS. Association of the 36-Item Short Form Health Survey Physical Component Summary Score With Patient Satisfaction and Improvement 2 Years After Total Knee Arthroplasty. JAMA Netw Open 2019; 2(2): e190062.;","DOI":"10.1001\/jamanetworkopen.2019.0062"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Shih IC, Chen HC, Chuang CH. An Unusual Cause of Refractory Gastric Ulcer. Gastroenterology 2023; 164(7): 1059-61.;","DOI":"10.1053\/j.gastro.2022.12.021"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"van Zanten SV, van der Knoop B. Gastric ulcer treatment: cure of Helicobacter pylori infection without subsequent acid-suppressive therapy: is it effective? European Journal of Gastroenterology & Hepatology 2008; 20(6): 489-91.;","DOI":"10.1097\/MEG.0b013e3282f427c8"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Li WQ, Zhang JY, Ma JL, Li ZX, Zhang L, Zhang Y, et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomised intervention trial. BMJ 2019; 366: l5016.;","DOI":"10.1136\/bmj.l5016"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Medakina I, Tsapkova L, Polyakova V, Nikolaev S, Yanova T, Dekhnich N, et al. Helicobacter pylori Antibiotic Resistance: Molecular Basis and Diagnostic Methods. Int J Mol Sci 2023; 24(11).;","DOI":"10.3390\/ijms24119433"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Sun Q, Yuan C, Zhou S, Lu J, Zeng M, Cai X, et al. Helicobacter pylori infection: a dynamic process from diagnosis to treatment. Front Cell Infect Microbiol 2023; 13: 1257817.;","DOI":"10.3389\/fcimb.2023.1257817"},{"key":"ref20","unstructured":"Shah N, Gossman W. Omeprazole. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: William Gossman declares no relevant financial relationships with ineligible companies: StatPearls, PublishingCopyright \u00a9 2024, StatPearls Publishing LLC.; 2024.;"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Yeo YH, Shiu SI, Ho HJ, Zou B, Lin JT, Wu MS, et al. First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis. Gut 2018; 67(1): 20-7.;","DOI":"10.1136\/gutjnl-2016-311868"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Yeh JA, Huang HK, Chou AL, Lin HJ, Feng CL, Kuo CJ, et al. Helicobacter pylori eradication with high-dose proton pump inhibitor-amoxicillin dual therapy: A systematic review and meta-analysis. International Journal of Antimicrobial Agents 2024; 63(6): 107-59.;","DOI":"10.1016\/j.ijantimicag.2024.107159"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Suo B, Tian X, Zhang H, Lu H, Li C, Zhang Y, et al. Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomised controlled trial. Chin Med J (Engl) 2023; 136(8): 933-40.;","DOI":"10.1097\/CM9.0000000000002629"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Poonyam P, Chotivitayatarakorn P, Vilaichone RK. High Effective of 14-Day High-Dose PPI-Bismuth-Containing Quadruple Therapy with Probiotics Supplement for Helicobacter Pylori Eradication: A Double Blinded-Randomized Placebo-Controlled Study. Asian Pacific journal of cancer prevention: APJCP 2019; 20(9): 2859-64.;","DOI":"10.31557\/APJCP.2019.20.9.2859"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Hamilton-Miller JM. The role of probiotics in the treatment and prevention of Helicobacter pylori infection. International Journal of Antimicrobial Agents 2003; 22(4): 360-6.;","DOI":"10.1016\/S0924-8579(03)00153-5"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Jiang X, Xu C, Liu B, Chen P, Xu Q, Zhang L. Efficacy and safety of bifidobacterium quadruple viable tablets in the treatment of Helicobacter pylori-infected peptic ulcer or gastritis patients: a systematic review and meta-analysis. BMC Infectious Diseases 2023; 23(1): 313.;","DOI":"10.1186\/s12879-023-08211-1"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Viazis N, Argyriou K, Kotzampassi K, Christodoulou DK, Apostolopoulos P, Georgopoulos SD, et al. A Four-Probiotics Regimen Combined with A Standard Helicobacter pylori-Eradication Treatment Reduces Side Effects and Increases Eradication Rates. Nutrients 2022; 14(3).;","DOI":"10.3390\/nu14030632"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Shi X, Zhang J, Mo L, Shi J, Qin M, Huang X. Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis. Medicine (Baltimore) 2019; 98(15): e15180.;","DOI":"10.1097\/MD.0000000000015180"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Noto JM, Piazuelo MB, Shah SC, Romero-Gallo J, Hart JL, Di C, et al. Iron deficiency linked to altered bile acid metabolism promotes Helicobacter pylori-induced inflammation-driven gastric carcinogenesis. The Journal of Clinical Investigation 2022; 132(10).;","DOI":"10.1172\/JCI147822"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Yu B, de Vos D, Guo X, Peng S, Xie W, Peppelenbosch MP, et al. IL-6 facilitates cross-talk between epithelial cells and tumor-associated macrophages in Helicobacter pylori-linked gastric carcinogenesis. Neoplasia (New York, NY). 2024; 50: 100981.;","DOI":"10.1016\/j.neo.2024.100981"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Watanabe J, Kotani K. The effect of Helicobacter pylori eradication on C-reactive protein: results from a meta-analysis. Archives of Medical Science: AMS 2022; 18(4): 958-64.;","DOI":"10.5114\/aoms\/130288"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Yu HJ, Liu W, Chang Z, Shen H, He LJ, Wang SS, et al. Probiotic BIFICO cocktail ameliorates Helicobacter pylori induced gastritis. World J Gastroenterol 2015; 21(21): 6561-71.;","DOI":"10.3748\/wjg.v21.i21.6561"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Li Z, Peng C, Sun Y, Zhang T, Feng C, Zhang W, et al. Both viable Bifidobacterium longum subsp. infantis B8762 and heat-killed cells alleviate the intestinal inflammation of DSS-induced IBD rats. Microbiology Spectrum 2024; 12(6): e0350923.;","DOI":"10.1128\/spectrum.03509-23"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Franceschi F, Genta RM, Sepulveda AR. Gastric mucosa: long-term outcome after cure of Helicobacter pylori infection. J Gastroenterol 2002; 37 Suppl 13: 17-23.;","DOI":"10.1007\/BF02990094"},{"key":"ref35","unstructured":"Feng X, Shi XMY. Correlations of recurrence of gastric cancer in patients after radical surgery with serum gastrointestinal hormones, vascular endothelial growth factors and serum anti-helicobacter pylori IgG antibody. J Buon 2020; 25(3): 1476-81.;"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Zhou H, Li Y, Lu W. Treatment Effects of Bifidobacterium Quadruple Viable Tablets Combined With Quadruple Therapy on Helicobacter Pylori-Infected Peptic Ulcer in Children. Clinical Pediatrics 2024: 99228241248717.;","DOI":"10.1177\/00099228241248717"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Russo F, Linsalata M, Orlando A. Probiotics against neoplastic transformation of gastric mucosa: effects on cell proliferation and polyamine metabolism. World J Gastroenterol 2014; 20(37): 13258-72.;","DOI":"10.3748\/wjg.v20.i37.13258"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Niu ZY, Li SZ, Shi YY, Xue Y. Effect of gastric microbiota on quadruple Helicobacter pylori eradication therapy containing bismuth. World J Gastroenterol 2021; 27(25): 3913-24.;","DOI":"10.3748\/wjg.v27.i25.3913"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Samara J, Moossavi S, Alshaikh B, Ortega VA, Pettersen VK, Ferdous T, et al. Supplementation with a probiotic mixture accelerates gut microbiome maturation and reduces intestinal inflammation in extremely preterm infants. Cell Host & Microbe 2022; 30(5): 696-711.e5.;","DOI":"10.1016\/j.chom.2022.04.005"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Wallace C, Gordon M, Sinopoulou V, Akobeng AK. Probiotics for management of functional abdominal pain disorders in children. The Cochrane database of systematic reviews 2023; 2(2): Cd012849.;","DOI":"10.1002\/14651858.CD012849.pub2"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Luo C, Peng S, Li M, Ao X, Liu Z. The Efficacy and Safety of Probiotics for Allergic Rhinitis: A Systematic Review and Meta-Analysis. Front Immunol 2022; 13: 848279.;","DOI":"10.3389\/fimmu.2022.848279"}],"container-title":["Journal of Medical Biochemistry"],"original-title":["Promena nivoa serumske koncentracije faktora nekroze tumora-alfa (TNF-a), interleukina-6 (IL-6), C-reaktivnog proteina (CRP), gastrina (GAS) i motilina (MTL) nakon le\u010denja Helicobacter pylori pozitivnog \u010dira na \u017eelucu"],"language":"en","link":[{"URL":"https:\/\/scindeks-clanci.ceon.rs\/data\/pdf\/1452-8258\/2025\/1452-82582507598C.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T12:08:23Z","timestamp":1761653303000},"score":1,"resource":{"primary":{"URL":"https:\/\/scindeks.ceon.rs\/Article.aspx?artid=1452-82582507598C"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5937\/jomb0-55373","relation":{},"ISSN":["1452-8258","1452-8266"],"issn-type":[{"value":"1452-8258","type":"print"},{"value":"1452-8266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}